abm | saCas9 Null Mutant NLS Protein | K147

ABMGood | saCas9 Null Mutant NLS Protein | K147

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement.

The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.

The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 NLS Null Mutant contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

Concentration:

10 µM, 1.30 mg/ml

Form:

Enzyme supplied with 10X Reaction Buffer

Alternate Name:

saCas9d, Dead saCas9, saCas9 Double Mutant, Nuclease-deficient saCas9, CRISPR-associated endonuclease Cas9 from Staphylococcus aureus

Reaction Buffer:

N/A

Reaction:

N/A

Notes:

N/A

Application:

N/A

Components:

N/A

Inactivation:

N/A

Source:

E. coli

Shipping conditions:

Ice Packs

Storage conditions:

Store all components at -20°C.

Storag Buffer:

10 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 1 mM DTT, 300 mM NaCl, and 50% (v/v) Glycerol.